Teva Pharmaceutical beats Q2 estimates, raises outlook

by
Contributor since / Followers

5 months ago

Teva Pharmaceutical press release (NYSE:TEVA): Q2 Non-GAAP EPS of $0.61 beats by $0.06.
Revenue of $4.2B (+7.7% Y/Y) beats by $150M.
Teva’s full year 2024 business outlook is raised to:
- Revenues of $16.0 – $16.4 billion
- AUSTEDO revenues of ~$1.6 billion
- Adjusted EBITDA of $4.6 – $5.0 billion
- Non-GAAP diluted EPS of $2.30 – $2.50

Tags: TEVA